摘要
目的探讨齐拉西酮对女性精神分裂症患者的远期疗效。方法将100例女性精神分裂症患者随机分为两组,分别予齐拉西酮和利培酮治疗,疗程8周,治疗结束后作1年的随访研究。用简明精神病评定量表(BPRS)、副反应量表(TESS)和生活质量综合评定问卷(GQOLI-74)进行相关评定。结果治疗前两组间各项评分均无统计学差异;治疗后两组BPRS、GQOLI-74总分及治疗依从性与治疗前相比均显著提高(P<0.05～0.01);两组有效率分别为94%和92%,无统计学差异(P>0.05);8周内两组间各时点BPRS总分无统计学差异。出院1年后,研究组的BPRS总分及社会功能分均优于对照组;复发率、再住院率均低于对照组。结论齐拉西酮是一种安全有效的非典型抗精神病药,能较好地控制精神症状;不良反应小,治疗依从性好,尤其适合女性精神分裂症患者的长期康复。
Objective To explore the long-term efficacy of ziprasidone in the treatment of female schizophrenic patients.Methods A total of 100 female patients with schizophrenia were randomly divided into two groups,respectively took ziprasidone or risperidone for 8 weeks,1 years follow-up study was carried out after the treatment.Using BPRS,TESS scale and life quality evaluation questionnaire（GQOLI-74）to assessment.Results There were no significant differences before treatment between two groups;After treatment,BPRS,GQOLI-74 scores and treatment compliance compared with before treatment were significantly increased（P0.05~0.01）;The effective rate in two groups were 94% and 92%,and there was no statistical difference（P0.05）;there were no significant differences in BPRS score between two groups at different time points.1 years after discharge,the BPRS total points and social functions were better in study group than in control group;the recurrence rate,readmission rates were lower than those of control group.Conclusion Ziprasidone is a safe and effective atypical antipsychotic drug,and can control the psychiatric symptoms;it has little adverse reactions,good treatment compliance,especially for female schizophrenic patients with long-term rehabilitation.
出处
《中国健康心理学杂志》
2012年第11期1624-1626,共3页
China Journal of Health Psychology
